Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million


Geneva, Switzerland, February 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it completed 2020 with a strong cash position of CHF18.7 million of cash and cash equivalents.

Read more:
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

Related Posts